Aarti Drugs Limited has scheduled its 41st Annual General Meeting for Saturday, September 26, 2026. The meeting will commence at 11:00 am through video conferencing or other audio-visual means.

The company published the notice in Financial Express and Pratahkal on September 1, 2026. This disclosure complies with Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The AGM aims to transact business as outlined in the notice convening the meeting. The event adheres to the Companies Act, 2013, and relevant circulars from the Ministry of Corporate Affairs and SEBI.

Shareholder Instructions

Shareholders holding shares in dematerialized mode must register or update their email addresses with their Depository Participants. Those holding physical shares should submit Form ISR-1 to the Registrar and Transfer Agent, MUFG Intime India Private Limited.

The notice and annual report for FY26 are available on the company website. Members can access these documents via BSE Limited, National Stock Exchange of India Limited, and NSDL websites.

Voting Process

Members may cast votes through an electronic voting system. Remote e-voting is available for all shareholders. Those attending the AGM who have not voted remotely can vote during the meeting using the e-voting system.

Queries regarding e-voting can be directed to evoting@nsdl.com .

Aarti Drugs Limited approved the 'Performance Stock Option Plan 2026' during its Board of Directors meeting on August 27, 2026. The plan authorizes the creation and grant of up to 8,00,000 (Eight lakh) Performance Stock Options (PSOs) convertible into equity shares of face value ₹10 each.

The eligible employees will receive these options in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The final implementation is subject to the approval of the company's members.

Plan Details

The Board meeting commenced at 11:30 am and concluded at 12:20 pm. Prior to the meeting, the trading window was closed from August 25, 2026, to August 29, 2026, as per the company's Code of Conduct for Prevention of Insider Trading.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rushikesh Deole, Company Secretary & Compliance Officer, confirmed the outcome.